Zobrazeno 1 - 10
of 19
pro vyhledávání: '"Grit Hehmann-Titt"'
Publikováno v:
Antibodies, Vol 3, Iss 1, Pp 92-115 (2014)
Targeted therapies for the treatment of cancer, but also inflammation and autoimmune diseases will reduce major side effects accompanied with conventional treatment modalities. The immunotoxin concept uses bacterial or plant toxins, coupled to antibo
Externí odkaz:
https://doaj.org/article/8141487616654464844d211b75b116a3
Publikováno v:
Antibodies, Vol 2, Iss 1, Pp 19-49 (2013)
Conventional cancer treatments lack specificity and often cause severe side effects. Targeted therapeutic approaches are therefore preferred, including the use of immunotoxins (ITs) that comprise cell-binding and cell death-inducing components to all
Externí odkaz:
https://doaj.org/article/d91f291eab064c248596b38da70950e6
Autor:
Mira Woitok, Christoph Stein, Rainer Fischer, Stefan Barth, Rolf Fendel, Judith Niesen, Grit Hehmann-Titt
Publikováno v:
Cancer Letters. 374:229-240
Human cytolytic fusion proteins (hCFPs) offer a promising immunotherapeutic approach for the treatment of solid tumors, avoiding the immunogenicity and undesirable side-effects caused by immunotoxins derived from plants or bacteria. The well-characte
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5ed22e62cf29e3e165e765ed4a225f00
https://doi.org/10.1016/j.canlet.2016.02.020
https://doi.org/10.1016/j.canlet.2016.02.020
Autor:
Stefan Barth, Edgar Jost, Theo Thepen, Grit Hehmann-Titt, Sonja Schiffer, Georg Melmer, Michael Huhn, Reinhard Rosinke
Publikováno v:
International Journal of Cancer. 135:1497-1508
CMML (chronic myelomonocytic leukemia) belongs to the group of myeloid neoplasms known as myelodysplastic and myeloproliferative diseases. In some patients with a history of CMML, the disease transforms to acute myelomonocytic leukemia (AMML). There
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6f1d4ae54898d6f809af10e24dd8d4fd
https://doi.org/10.1002/ijc.28786
https://doi.org/10.1002/ijc.28786
Publikováno v:
Antibodies, Vol 3, Iss 1, Pp 92-115 (2014)
Targeted therapies for the treatment of cancer, but also inflammation and autoimmune diseases will reduce major side effects accompanied with conventional treatment modalities. The immunotoxin concept uses bacterial or plant toxins, coupled to antibo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::426e803da88b51b164fd476b425e1628
http://www.mdpi.com/2073-4468/3/1/92
http://www.mdpi.com/2073-4468/3/1/92
Publikováno v:
Antibodies, Vol 2, Iss 1, Pp 19-49 (2013)
Conventional cancer treatments lack specificity and often cause severe side effects. Targeted therapeutic approaches are therefore preferred, including the use of immunotoxins (ITs) that comprise cell-binding and cell death-inducing components to all
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a0d15b59b3dff7defbbe162871a719c5
https://doi.org/10.3390/antib2010019
https://doi.org/10.3390/antib2010019
Autor:
Judith Niesen, Grit Hehmann-Titt, Rolf Fendel, Hannes Brehm, Christoph Stein, Rainer Fischer, Stefan Barth, Georg Melmer
Publikováno v:
Journal of cancer research and clinical oncology. 141(12)
The epidermal growth factor receptor (EGFR) is overexpressed in many solid tumors. EGFR-specific monoclonal antibodies (mAbs), such as cetuximab and panitumumab, have been approved for the treatment of colorectal and head and neck cancer. To increase
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2014f26ae812ddf48ce5d0b4e3aa0ce1
https://pubmed.ncbi.nlm.nih.gov/25899161
https://pubmed.ncbi.nlm.nih.gov/25899161
Autor:
Sonja, Schiffer, Reinhard, Rosinke, Edgar, Jost, Grit, Hehmann-Titt, Michael, Huhn, Georg, Melmer, Stefan, Barth, Theo, Thepen
Publikováno v:
International journal of cancer. 135(6)
CMML (chronic myelomonocytic leukemia) belongs to the group of myeloid neoplasms known as myelodysplastic and myeloproliferative diseases. In some patients with a history of CMML, the disease transforms to acute myelomonocytic leukemia (AMML). There
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::2214f43254ab68e9e4e3c14462c57c69
https://pubmed.ncbi.nlm.nih.gov/24523193
https://pubmed.ncbi.nlm.nih.gov/24523193
Autor:
Klose, Diana1,2, Woitok, Mira1,3, Niesen, Judith1, Beerli, Roger R.4, Grawunder, Ulf4, Fischer, Rainer1,3, Barth, Stefan2,5, Fendel, Rolf1 rolf.fendel@ime.fraunhofer.de, Nachreiner, Thomas2
Publikováno v:
PLoS ONE. 7/13/2017, Vol. 12 Issue 7, p1-21. 21p.
Autor:
Berges, Nina1, Hehmann-Titt, Grit2, Hristodorov, Dmitrij1, Melmer, Georg2, Thepen, Theo3 thepen@ime.fraunhofer.de, Barth, Stefan1,3 barth@hia.rwth-aachen.de
Publikováno v:
Antibodies (2073-4468). Mar2014, Vol. 3 Issue 1, p92-115. 24p.